Calcipotriol/betamethasone dipropionate - Drug Delivery Solutions ApS

Drug Profile

Calcipotriol/betamethasone dipropionate - Drug Delivery Solutions ApS

Alternative Names: MC2 01; MC2-14; PADcombo; PADscalp

Latest Information Update: 17 Dec 2015

Price : $50

At a glance

  • Originator Drug Delivery Solutions ApS
  • Class Anti-inflammatories; Antipsoriatics; Cyclohexenes; Dihydroxycholecalciferols; Fluorinated steroids; Glucocorticoids; Indenes; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Plaque psoriasis
  • Phase Unknown Psoriasis

Most Recent Events

  • 08 May 2015 Drug Delivery Solutions completes a phase II trial in Plaque psoriasis in Germany (EudraCT2013-005003-14)
  • 02 Apr 2014 Phase-II clinical trials in Plaque psoriasis in Germany (Topical, ointment)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top